Objective To evaluate changes in vascular and musculoskeletal involvement in subjects in
the Scleroderma Lung Study, a multicenter, double‐blind, randomized, controlled trial …

Objective. To compare safety and efficacy outcomes between the cyclophosphamide (CYC)
arms of Scleroderma Lung Study (SLS) I and II. Methods. Participants enrolled in the CYC …

Objective To study the clinical implications of a skin thickness score≥ 20 at first visit and of
softening of sclerodermatous skin in a cohort of systemic sclerosis (SSc) patients with diffuse …

Objective To assess the course of the modified Rodnan skin thickness score (MRSS) in 3
large, multicenter, double‐blind, randomized controlled trials (RCTs) of patients with diffuse …

Objectives: Pulmonary fibrosis is a leading cause of death in systemic sclerosis (SSc). This
report examines the differences at baseline and over 12 months between patients with …

Systemic sclerosis (scleroderma; SSc) is an autoimmune rheumatic disease with high
clinical burden and unmet need due to connective tissue fibrosis and vascular damage. It …

Objective The natural history of changes in skin thickening in diffuse scleroderma is quite
variable, but the significance of these changes is not clear. Clinical trials are using changes …

Background Previous studies have shown the relationship between higher skin thickness
score and the existence of organ involvements in systemic sclerosis (SSc). Here, we firstly …

Background European data indicate that systemic sclerosis (SSc)-related death rates are
increasing, thus raising concerns about SSc's optimal management. Herein, we describe …

Background Scleroderma is a systemic autoimmune disease characterized mainly by skin
manifestations and involvement of various visceral organs, especially the lungs. Lung …